JP7108320B2 - 片頭痛の症状を管理するためのグリセリル３－ヒドロキシブチラート - Google Patents

片頭痛の症状を管理するためのグリセリル３－ヒドロキシブチラート Download PDF

Info

Publication number
JP7108320B2
JP7108320B2 JP2019534701A JP2019534701A JP7108320B2 JP 7108320 B2 JP7108320 B2 JP 7108320B2 JP 2019534701 A JP2019534701 A JP 2019534701A JP 2019534701 A JP2019534701 A JP 2019534701A JP 7108320 B2 JP7108320 B2 JP 7108320B2
Authority
JP
Japan
Prior art keywords
hydroxybutyrate
glyceryl
subject
compound
migraine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019534701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502250A (ja
JP2020502250A5 (enExample
Inventor
ハシム、サミ
Original Assignee
ニューロエナジー ベンチャーズ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロエナジー ベンチャーズ、インコーポレイテッド filed Critical ニューロエナジー ベンチャーズ、インコーポレイテッド
Publication of JP2020502250A publication Critical patent/JP2020502250A/ja
Publication of JP2020502250A5 publication Critical patent/JP2020502250A5/ja
Application granted granted Critical
Publication of JP7108320B2 publication Critical patent/JP7108320B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2019534701A 2016-12-23 2017-11-30 片頭痛の症状を管理するためのグリセリル３－ヒドロキシブチラート Active JP7108320B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/389,828 US20180177753A1 (en) 2016-12-23 2016-12-23 Glyceryl 3-hydroxybutyrates for migraine symptom management
US15/389,828 2016-12-23
PCT/US2017/063832 WO2018118369A1 (en) 2016-12-23 2017-11-30 Glyceryl 3-hydroxybutyrates for migraine symptom management

Publications (3)

Publication Number Publication Date
JP2020502250A JP2020502250A (ja) 2020-01-23
JP2020502250A5 JP2020502250A5 (enExample) 2021-01-14
JP7108320B2 true JP7108320B2 (ja) 2022-07-28

Family

ID=62624821

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019534701A Active JP7108320B2 (ja) 2016-12-23 2017-11-30 片頭痛の症状を管理するためのグリセリル３－ヒドロキシブチラート

Country Status (13)

Country Link
US (2) US20180177753A1 (enExample)
EP (1) EP3558458B1 (enExample)
JP (1) JP7108320B2 (enExample)
KR (1) KR102390608B1 (enExample)
CN (1) CN110167637B (enExample)
BR (1) BR112019012431A2 (enExample)
CA (1) CA3046350C (enExample)
ES (1) ES2962879T3 (enExample)
IL (1) IL267540B (enExample)
MX (1) MX389468B (enExample)
MY (1) MY190308A (enExample)
PT (1) PT3558458T (enExample)
WO (1) WO2018118369A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
WO2018115158A1 (en) 2016-12-21 2018-06-28 Universitäts-Kinderspital Beider Basel Migraine prevention and treatment
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
ES2965646T3 (es) * 2019-01-17 2024-04-16 Ketolipix Therapeutics Gmbh Procedimiento para la producción de lípidos que contienen unidades estructurales a base de glicéridos de ácidos hidroxicarboxílicos
WO2020147978A1 (de) * 2019-01-17 2020-07-23 Ioi Oleo Gmbh Verfahren zur herstellung von glyceriden von hydroxycarbonsäuren
IL278422B (en) * 2019-03-14 2022-09-01 Neuroenergy Ventures Inc A flavor masking formulation for ketone body compounds
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
CN113710243A (zh) * 2019-05-30 2021-11-26 神经活力投资公司 甘油三(β-羟基丁酸酯)与神经元短暂性脑缺血发作
CN114008014B (zh) * 2019-06-12 2024-03-22 凯托利皮克斯治疗有限责任公司 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
IT201900018488A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di preparazione del tris-(3-idrossibutirrato)-gliceril estere
IT201900018491A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di purificazione del tris-(3-idrossibutirrato)-gliceril estere
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
AU2022387742A1 (en) * 2021-11-12 2024-06-27 Arxada Ag Polyol-derived compounds
WO2023094654A1 (en) 2021-11-26 2023-06-01 Arxada Ag Acetoacetate based ketals
US12023382B2 (en) 2022-01-18 2024-07-02 Today Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
US12622967B2 (en) * 2022-01-18 2026-05-12 Today, Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
EP4605371A1 (en) 2022-10-18 2025-08-27 Arxada AG Polyol-derived compounds
WO2025074001A2 (en) 2023-10-05 2025-04-10 Arxada Ag Enzymatic reduction of acetoacetate
WO2025196156A1 (en) 2024-03-20 2025-09-25 Arxada Ag Continuous hydrogenation process of acetoacetate esters
WO2025224319A1 (en) 2024-04-25 2025-10-30 Arxada Ag Reduction of acetoacetate esters in the presence of amines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005818A1 (en) 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
US20080058416A1 (en) 2004-05-12 2008-03-06 David Greenwood Cns Modulators
US20150065571A1 (en) 2013-08-07 2015-03-05 Tdeltas Limited Ketone body and ketone body ester for reducing muscle breakdown

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124589B2 (en) 2000-05-01 2012-02-28 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
AU2010207597A1 (en) * 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
CA2873057C (en) 2011-05-09 2020-02-25 University Of South Florida The use of ketone esters for prevention of cns oxygen toxicity
US20140072654A1 (en) 2011-12-23 2014-03-13 Savind, Inc. Cancer with metabolic therapy and hyperbaric oxygen
FR2997302B1 (fr) * 2012-10-29 2015-02-06 Assist Publ Hopitaux De Paris Prevention et traitement des deficits en pyruvate deshydrogenase
WO2014071389A1 (en) 2012-11-05 2014-05-08 Veech Richard L Ketone bodies to protect tissues from damage by ionizing radiation
EP2925308B1 (en) 2012-11-28 2019-12-25 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
BR112015024186B1 (pt) 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
CA2973342A1 (en) 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
US20160078782A1 (en) * 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
US20180200220A1 (en) 2015-07-10 2018-07-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
SG11201809211QA (en) 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2018009208A1 (en) 2016-07-08 2018-01-11 Cognate Nutritionals, Inc. Nutritional mitiggation of the cns effects of traumatic brain injury
JP2019526607A (ja) 2016-09-12 2019-09-19 ユニバーシティ・オブ・サウス・フロリダ ケトンにより改善された神経再生
WO2018115158A1 (en) 2016-12-21 2018-06-28 Universitäts-Kinderspital Beider Basel Migraine prevention and treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080058416A1 (en) 2004-05-12 2008-03-06 David Greenwood Cns Modulators
WO2008005818A1 (en) 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
US20150065571A1 (en) 2013-08-07 2015-03-05 Tdeltas Limited Ketone body and ketone body ester for reducing muscle breakdown

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HASHIM, Sami A. and VANITALLIE, Theodore B.，Ketone body therapy: from the ketogenic diet to the oral administration of ketone ester，Journal of Lipid Research，2014年，Vo. 55，pp. 1818-1826
KOSSOFF, Eric C. and HARTMAN, Adam L.，Ketogenic Diets: New Advances for Metabolism-Based Therapies，Current Opinion in Neurology，2012年，Vo. 25, No. 2，pp. 173-178
LORENZO, C. Di et al.，Migraine improvement during short lasting ketogenesis: a proof-of-concept study，European Journal of Neurology，2014年，Vol. 22, No. 1，pp. 170-177
LORENZO, Cherubino Di et al.，Diet transiently improves migraine in two twin sisters: possible role of ketogenesis?，Functional Neurology，2013年，Vol. 28, No. 4，pp. 305-308
MCCLEARY, Larry，Migraine Headaches - Rethinking an Old Maladay，https://www.brainblogger.com/2008/01/28/rethinking-an-old-malady/ Brain Blogger 2008/01/28，2008年，pp. 1-2

Also Published As

Publication number Publication date
MX2019006844A (es) 2019-08-16
BR112019012431A2 (pt) 2020-04-14
IL267540A (en) 2019-08-29
US20190117612A1 (en) 2019-04-25
CA3046350A1 (en) 2018-06-28
CN110167637B (zh) 2023-03-14
MX389468B (es) 2025-03-20
JP2020502250A (ja) 2020-01-23
PT3558458T (pt) 2023-11-27
US20180177753A1 (en) 2018-06-28
EP3558458A1 (en) 2019-10-30
CA3046350C (en) 2022-08-16
EP3558458B1 (en) 2023-10-18
KR102390608B1 (ko) 2022-04-25
MY190308A (en) 2022-04-13
KR20190099465A (ko) 2019-08-27
CN110167637A (zh) 2019-08-23
US10792269B2 (en) 2020-10-06
IL267540B (en) 2022-07-01
WO2018118369A1 (en) 2018-06-28
EP3558458A4 (en) 2020-08-12
ES2962879T3 (es) 2024-03-21

Similar Documents

Publication Publication Date Title
CN110167637B (zh) 3-羟基丁酸甘油酯用于偏头痛症状管理
JP7278593B2 (ja) 外傷性脳損傷のためのグリセリル３－ヒドロキシブチラート
DK2691086T3 (en) COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS
CN101765427A (zh) 在简易精神状态检查值为24-26的受试者中改善记忆
JPH02104522A (ja) 脂肪酸を含有する医薬用組成物
JP2017519028A (ja) 重度の高トリグリセリド血症の処置
CN116490181A (zh) 在人中施用β-羟基丁酸和相关化合物用于治疗和/或预防呼吸道疾病
HK40012930B (en) Glyceryl 3-hydroxybutyrates for migraine symptom management
US20240382445A1 (en) Methods of adjuvant therapy
US7208522B1 (en) Methods and compositions for the prevention and treatment of Syndrome X
Kłęk et al. The use of intravenous emulsions containing omega-3 unsaturated fatty acids in clinical practice: recommendations of a team of experts
HK40012930A (en) Glyceryl 3-hydroxybutyrates for migraine symptom management
HK40012461A (en) Glyceryl 3-hydroxybutyrates for traumatic brain injury
WO2002009692A1 (en) Methods and compositions for the attenuation and/or prevention of stress/catabolic responses
Furman et al. Workshop: Dietary Management of Hyperlipoproteinemias
NZ616554B2 (en) Compositions for the treatment of neurologic disorders
HK1194665B (en) Compositions for the treatment of neurologic disorders

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20190704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220601

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220708

R150 Certificate of patent or registration of utility model

Ref document number: 7108320

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250